Loading
Whitehawk Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Dalal Anupam, was filed 30 Aug 2021.
Whitehawk Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Whitehawk Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. 4 insiders have disclosed 21 filings since 23 October 2025.
All open-market trades in the period are sales: 14 sales worth €2.2M, by 3 insiders, with no purchase on record. At €496k, the sale published on 17 April 2026 by Giacobello Scott M. is the largest of the period.
Compared with its exchange (3,167 companies, median 24 filings), a count of 21 filings is below the norm. Over the whole record (from 2017), the tally stands at 47 purchases and 84 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 7.1 m USD and net income of -20.6 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
166
Thresholds
n/a
Buy Volume
€48M
47 ops. · all time
Sell Volume
€7M
84 ops. · all time
Who traded when
BuySaleDavid James Lennon7 sales
Bryan Ball6 sales
Scott M. Giacobello4 sales
Since the insiders bought
- -48.0%Entry US$26.05 · Close at T+365 US$13.55
- -48.0%Entry US$26.05 · Close at T+365 US$13.55
- +55.6%Entry US$12.15 · Close at T+365 US$18.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,224 of 26,250 companies
30.0
score / 100
Value9
Quality51
FCF yld-54%
Earn yld-11%
EV/EBITDA·
ROE-45%
Gross mgn89%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.19
Analyst consensus
7 analysts1.78/5
US$4.00Target US$7.71(+142%)US$10.00
Income statement
RevenueUS$7.1M
Gross profitUS$6.4M89% margin
EBITDA-US$20.5M-287% margin
Net income-US$20.6M-288.3% margin
Valuation
PER (forward)-3.2x
P/Book1.0x
Beta0.91
Balance sheet & cash
Market capUS$181.9M
Free Cash Flow-US$98M
Profitability & ownership
ROE-45.0%
ROA-28.7%
% insiders12.6%
% institutions81.1%
Last declaration on 30 July 2026
Declarations166 total
1,275,510 shares@ US$3.920.25% mcap100.0% of flowCommon StockSEC:0001602474-26-000004:0
77,000 shares@ US$3.8633.6% of flowCommon StockSEC:0001754154-26-000010:0
141,600 shares@ US$4.1366.4% of flowCommon StockSEC:0001754154-26-000010:1
92,460 shares@ US$3.6453.3% of flowCommon StockSEC:0001766522-26-000011:1
26,389 shares@ US$3.4614.5% of flowCommon StockSEC:0001766522-26-000011:0
50,000 shares@ US$3.5728.5% of flowCommon StockSEC:0001766522-26-000009:0
6,596 shares@ US$3.433.6% of flowCommon StockSEC:0001766522-26-000009:1
14,500 shares@ US$3.384.7% of flowCommon StockSEC:0001995275-26-000012:0
102,395 shares@ US$3.5134.7% of flowCommon StockSEC:0001995275-26-000008:0
94,087 shares@ US$3.4330.8% of flowCommon StockSEC:0001995275-26-000008:1
63,945 shares@ US$3.4020.8% of flowCommon StockSEC:0001995275-26-000008:2
26,858 shares@ US$3.489.0% of flowCommon StockSEC:0001995275-26-000006:1
366,532 sharesCommon StockSEC:0001766522-26-000005:0
473,902 sharesCommon StockSEC:0001754154-26-000005:0
775,828 sharesCommon StockSEC:0001995275-26-000006:0
1,834 shares@ US$3.310.7% of flowCommon StockSEC:0001766522-26-000002:1
5,100 shares@ US$3.311.5% of flowCommon StockSEC:0001995275-26-000002:1
2,594 shares@ US$3.310.7% of flowCommon StockSEC:0001754154-26-000002:1
16,250 sharesCommon StockSEC:0001995275-26-000002:0
5,000 sharesCommon StockSEC:0001766522-26-000002:0
6,750 sharesCommon StockSEC:0001754154-26-000002:0
1,561,000 shares@ US$2.4014.4% of flowCommon StockSEC:0001415889-25-007096:0
2,147 shares@ US$2.350.6% of flowCommon StockSEC:0001415889-25-006676:1
100,000 shares@ US$2.4029.6% of flowCommon StockSEC:0001415889-25-006676:2
5,000 sharesCommon StockSEC:0001415889-25-006676:0
25 of 166 declarations
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. It employs innovative approaches to target the underlying mechanisms of these conditions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
